Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109702 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
A Phase 3 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT05109702: Completed Phase 3 study, sponsored by HanAll BioPharma Co..
NCT05109702 is a Phase 3 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 260 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05109702, a Phase 3 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
Primary Outcome
CCSS was graded using the Ora Calibra® Corneal and Conjunctival Fluorescein Staining Scale. The Ora Calibra® Corneal and Conjunctival Staining Scale ranged 0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe; lower score indicated improvement.
Interventions
- DRUG Placebo
- DRUG 0.25% Tanfanercept Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-05-06 |
| Phase | Phase 3 |
What the finished NCT05109702 record still lists
NCT05109702 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05109702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05109702 about?
NCT05109702 is a clinical study titled "A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye". The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT05109702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2021-11-18. Estimated completion is 2022-05-06.
What interventions are being tested in trial NCT05109702?
The interventions under investigation include: Placebo (DRUG), 0.25% Tanfanercept Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05109702?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05109702's enrollment target sits among peer trials
260 1230th of 2000 higher than 767 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI